Molecular Partners Ag ADR (MOLN)

$4.04 -0.16 (-3.89%)
Market Cap 144.12M
Revenue (ttm) 5.65M
Net Income (ttm) -61.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,086.55%
Debt to Equity Ratio 0.00
Volume 79,158
Avg Vol 10,226
Day's Range N/A - N/A
Shares Out 40.38M
Stochastic %K 93%
Beta 1.16
Analysts Strong Sell
Price Target $10.88

Latest News on MOLN

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Apr 25, 2025, 4:00 PM EDT - 2 days ago

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Apr 16, 2025, 12:00 PM EDT - 12 days ago

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Molecular Partners to hold three poster presentations at AACR 2025

Mar 25, 2025, 4:00 PM EDT - 4 weeks ago

Molecular Partners to hold three poster presentations at AACR 2025

Molecular Partners Publishes Invitation to Annual General Meeting 2025

Mar 25, 2025, 12:00 PM EDT - 4 weeks ago

Molecular Partners Publishes Invitation to Annual General Meeting 2025

Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 11:59 AM EST - 7 weeks ago

Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Mar 6, 2025, 4:00 PM EST - 7 weeks ago

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Feb 28, 2025, 1:00 AM EST - 2 months ago

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

Jan 15, 2025, 3:04 PM EST - 3 months ago

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Jan 12, 2025, 1:00 PM EST - 3 months ago

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Jan 12, 2025, 1:00 PM EST - 3 months ago

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Dec 17, 2024, 4:00 PM EST - 4 months ago

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Dec 8, 2024, 12:00 PM EST - 5 months ago

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Nov 7, 2024, 4:00 PM EST - 6 months ago

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Oct 31, 2024, 4:00 PM EDT - 6 months ago

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Oct 25, 2024, 1:00 AM EDT - 6 months ago

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Oct 22, 2024, 1:00 AM EDT - 6 months ago

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Oct 22, 2024, 1:00 AM EDT - 6 months ago

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Oct 4, 2024, 1:00 AM EDT - 7 months ago

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Sep 27, 2024, 1:00 AM EDT - 7 months ago

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Aug 26, 2024, 4:00 PM EDT - 8 months ago

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Aug 7, 2024, 5:37 AM EDT - 9 months ago

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Jun 17, 2024, 1:00 AM EDT - 11 months ago

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Jun 14, 2024, 1:00 AM EDT - 11 months ago

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Jun 11, 2024, 1:00 AM EDT - 11 months ago

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

Jun 1, 2024, 8:00 AM EDT - 11 months ago

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

May 16, 2024, 4:00 PM EDT - 1 year ago

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Apr 29, 2024, 11:00 AM EDT - 1 year ago

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Life Science Cares Launches in Switzerland

Apr 19, 2024, 11:12 AM EDT - 1 year ago

Life Science Cares Launches in Switzerland

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Apr 17, 2024, 11:12 AM EDT - 1 year ago

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Mar 26, 2024, 9:26 AM EDT - 1 year ago

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript

Mar 15, 2024, 11:20 AM EDT - 1 year ago

Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Mar 14, 2024, 4:00 PM EDT - 1 year ago

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Mar 1, 2024, 4:00 PM EST - 1 year ago

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Jan 7, 2024, 4:00 PM EST - 1 year ago

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Jan 5, 2024, 4:00 PM EST - 1 year ago

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Dec 14, 2023, 1:00 AM EST - 1 year ago

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Dec 10, 2023, 12:00 PM EST - 1 year ago

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Nov 14, 2023, 1:00 AM EST - 1 year ago

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

Nov 2, 2023, 2:00 AM EDT - 1 year ago

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

Nov 1, 2023, 2:00 AM EDT - 1 year ago

Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio

Oct 26, 2023, 4:00 PM EDT - 1 year ago

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Sep 13, 2023, 1:00 AM EDT - 1 year ago

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Molecular Partners Reports H1 2023 Corporate Highlights and Financials

Aug 24, 2023, 4:00 PM EDT - 1 year ago

Molecular Partners Reports H1 2023 Corporate Highlights and Financials

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

Jun 27, 2023, 1:00 AM EDT - 1 year ago

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

May 25, 2023, 5:01 PM EDT - 2 years ago

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

May 16, 2023, 4:00 PM EDT - 2 years ago

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

May 11, 2023, 4:00 PM EDT - 2 years ago

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero

Apr 20, 2023, 2:08 AM EDT - 2 years ago

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero

Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR

Apr 14, 2023, 1:00 AM EDT - 2 years ago

Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR